Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Apollomics Acquires Rights to Novel Iterion Oncology Candidate

publication date: Feb 11, 2021

Apollomics, a California-Hangzhou oncology company, acquired greater China rights to an Iterion candidate for desmoid tumors, a rare type of sarcoma that has no approved therapies. The candidate, tegavivint, inhibits nuclear β-catenin that binds to TBL1 (Transducin βeta-like Protein One), a downstream target in the Wnt-signaling pathway. Tegavivint is currently in a Phase I/IIa clinical trial in progressive desmoid tumors. It has also shown pre-clinical activity in acute myeloid leukemia and non-small cell lung cancer. Iterion, located in Houston, Texas, develops beta-catenin modulators for cancer. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here